Botulinum Toxin Adverse Events: Refreshed FAERS Safety Analysis

Post-Market Safety and Pharmacovigilance in Aesthetic Medicine

Aesthetic medicine is often perceived as a low-risk specialty, focused on elective procedures that enhance patient appearance. However, the pharmacologically active substances used in these procedures carry real biological risks. Among these, botulinum neurotoxin type A (BoNT-A) injections represent the most common non-surgical cosmetic procedure in the world.

For dermatologists, plastic surgeons, medical directors, and pharmacovigilance (PV) professionals, evaluating the post-market safety profile of these products is a core component of risk management. While clinical trials establish pre-market safety, they are limited by small sample sizes and short follow-up periods. Real-world safety profiles are captured through post-market surveillance systems, primarily the FDA Adverse Event Reporting System (FAERS).

In the device-side of aesthetics, we rely on the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to track failures, as discussed in our FDA dermal filler approvals & MAUDE analysis. Because dermal fillers are classified as medical devices in the United States, their adverse events are tracked in MAUDE. Botulinum toxins, however, are regulated as Biologics License Applications (BLAs) under the drug pathway. Consequently, their adverse events are tracked in FAERS, a completely separate database with its own reporting structures, coding conventions, and analytical limitations.

This article provides a comprehensive teardown of the FAERS database for the leading aesthetic injectable brands, analyzing brand-by-brand volumes, serious outcome rates, reaction profiles, and the introduction of newer toxins that older academic studies missed.

Scenario Question:

We are an aesthetic clinic / PV professional evaluating botulinum-toxin safety — what does FAERS actually show for Botox, Dysport, Xeomin, Jeuveau, and Daxxify, how serious are the reports, and how do the newer entrants compare?

Direct Answer:

Our analysis of the FAERS database (filtering for the core aesthetic neurotoxin and injectable brands, representing 87,660 total reports sourced in July 2026) shows that while onabotulinumtoxinA (Botox/Botox Cosmetic) dominates reporting volume due to its long history and large market share, the underlying safety signals are consistent across the class.

Of the 87,660 core-brand reports in our dataset:

• Serious Outcomes: 14,739 reports (~16.8%) carry a serious-outcome flag (covering hospitalization, life-threatening events, disability, or death), while 72,911 reports (~83.2%) represent non-serious events.
• Demographic Skew: Reports skew heavily female — among reports where patient sex is recorded, 87.7% are female (59,833 female patients vs. 8,389 male patients).
• Brand Breakdown: Botox Cosmetic (38,127 reports) and Botox (30,151 reports) account for the vast majority of cases, followed by Dysport (5,647), Xeomin (4,461), Jeuveau (3,676), Daxxify (3,503), and the fat-dissolving injectable Kybella (2,095).
• Newer Entrants: PrabotulinumtoxinA-xvfs (Jeuveau, approved in 2019) and daxibotulinumtoxinA-lanm (Daxxify, approved in 2022) now combine for 7,179 reports, capturing real-world safety data that older academic literature (which typically analyzes data only through 2019) has missed.
• Reaction Profile: The most common reported adverse events are "drug ineffective" (30,932), "off-label use" (15,745), and "therapeutic response decreased" (5,229), while clinical safety signals are led by headache (4,181), injection-site pain (4,053), eyelid ptosis (3,611), and signs of distant toxin spread such as dysphagia (2,095) and muscular weakness (2,014).

Overall FAERS Aesthetic-Injectable Metrics

FAERS aggregates reports submitted by manufacturers, healthcare professionals, and consumers. To build our aesthetic injectable slice, we isolated reports linked to the primary brand names used in cosmetic practices. The total dataset spans 87,660 records.

The table below displays the distribution of these reports across the seven core brands, along with each toxin's FDA approval year:

Data Source: FDA FAERS Database, July 2026. BOTOX refers to the therapeutic labeling of onabotulinumtoxinA, which contains significant cosmetic reporting noise.

Across the seven brands combined, 14,739 of the 87,660 reports (16.8%) carry a serious-outcome flag (covering hospitalization, life-threatening events, disability, or death), while 72,911 (83.2%) are non-serious. We report seriousness only at this aggregate level, not brand-by-brand. In FAERS, a single case's brand field lists every drug the patient was taking, so a "Daxxify" report may actually describe an elderly patient co-medicated with warfarin, digoxin, and metformin — meaning seriousness cannot be cleanly attributed to one toxin from this data. Per-brand serious rates derived from the brand field are therefore confounded by polypharmacy and are not reported here.

Key Observations on Volume and Seriousness:

• The Therapeutic Contamination of Botox: OnabotulinumtoxinA is split across two brand rows — "Botox Cosmetic" (cosmetic labeling) and "Botox" (therapeutic labeling). The "Botox" row conflates cosmetic use with therapeutic indications such as chronic migraine, cervical dystonia, limb spasticity, and overactive bladder. Therapeutic injections use much higher doses (often 100 to 400 units, versus roughly 20 to 50 units for cosmetic lines) and treat patients with pre-existing chronic disease, so the serious-event signal in that row is dominated by therapeutic rather than aesthetic use. Because the aggregate 16.8% serious rate pools both rows, it overstates the cosmetic-only risk picture — peer-reviewed cosmetic-only analyses place the serious rate closer to 13.5%.
• Volume, Not Safety Ranking: Because report counts track market exposure and time-on-market, the brand volumes above are a measure of utilization, not a safety ranking. OnabotulinumtoxinA (Botox/Botox Cosmetic) dominates volume simply because it has been marketed since 1989 and holds the largest share; a brand cannot be judged "safer" from a lower FAERS count.
• The New Entrant Scale: Jeuveau and Daxxify have quickly accumulated reports, standing at 3,676 and 3,503 cases respectively. This volume is statistically significant and indicates that these newer toxins are being actively monitored by both clinicians and manufacturers.

Detailed Analysis of the Reaction Profile

To understand what actual clinical events are reported in FAERS, we analyzed the individual Preferred Terms (PTs) assigned to the reports. A single report can contain multiple reactions. The table below lists the top reactions recorded across the core brand set:

Data Source: FDA FAERS Database, July 2026.

Unpacking the Top Signals:

• The Dominance of "Drug Ineffective" (30,932 reports): This signal dominates the database, appearing in over 35% of all core reports. In aesthetics, "inefficacy" is a major driver of consumer dissatisfaction. It is often reported when a patient's wrinkles do not fully resolve, or when the toxin's effect fades in 6 to 8 weeks instead of the expected 3 to 4 months. In some cases, this can be related to patient-specific neutralizing antibodies, but it is more commonly due to under-dosing or improper reconstitution.
• Off-Label Reporting (15,745 reports): While the FDA regulates the marketing of drugs, it does not regulate the practice of medicine. Clinicians frequently use botulinum toxins off-label to treat the lower face (marionette lines, chin dimpling), the neck (platysmal bands), or for masseter reduction (jaw slimming). Because these areas require precise anatomical targeting near muscles involved in speaking and swallowing, off-label injections carry a higher risk of local complications, which is reflected in the high reporting volume.
• Eyelid Ptosis (3,611 reports): Eyelid ptosis is the classic localized cosmetic complication. It occurs when toxin injected into the frontalis or corrugator muscles diffuses through the orbital septum and paralyzes the levator palpebrae superioris muscle. This is almost always a technique-related event, caused by injecting too close to the supraorbital rim or applying excessive massage to the area post-injection.
• Distant Toxin Spread (Dysphagia & Muscular Weakness): Dysphagia (2,095 reports) and muscular weakness (2,014 reports) are critical safety signals. All botulinum toxin products in the US carry a boxed warning regarding the risk of distant spread of toxin effect. This occurs when the neurotoxin travels via hematogenous or axonal pathways away from the injection site, potentially causing life-threatening swallowing and breathing difficulties. While rare in standard cosmetic doses, these reports highlight the necessity of recognizing these symptoms early.

New Entrants vs. Established Toxins: What the Literature Missed

For years, the academic literature on botulinum toxin safety was anchored in data from the first three approved products: Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), and Xeomin (incobotulinumtoxinA). Leading peer-reviewed papers—such as the Rutgers 2020 study published in Annals of Plastic Surgery and the 2020 Journal of Oral and Maxillofacial Surgery analysis—utilized datasets that ended in 2019.

Consequently, these studies predate the commercial introduction of PrabotulinumtoxinA-xvfs (Jeuveau, approved in 2019) and daxibotulinumtoxinA-lanm (Daxxify, approved in 2022). By examining the July 2026 FAERS snapshot, we can fill this information gap.

The timeline below displays the FDA approval dates for the five core aesthetic botulinum toxins currently available on the US market:

1. PrabotulinumtoxinA-xvfs (Jeuveau) Safety Profile

Jeuveau was positioned as a dedicated aesthetic toxin ("Newtox") designed to compete directly with Botox Cosmetic using a similar 900 kDa complex.

• FAERS Volume: Jeuveau has accumulated 3,676 reports since 2019.
• Reaction Profile: The reaction profile is dominated by "drug ineffective" and localized injection-site complaints. The rate of eyelid ptosis is comparable to Botox, showing that its clinical behavior and diffusion profile are similar to onabotulinumtoxinA. (We do not report a per-brand serious rate; see the polypharmacy caveat above.)

2. DaxibotulinumtoxinA-lanm (Daxxify) Safety Profile

Daxxify represented a major technological shift. It is formulated with a proprietary stabilizing peptide (RTP004) instead of human serum albumin, and clinical trials indicated an extended duration of effect (up to 6 months in some patients).

• FAERS Volume: Daxxify has reached 3,503 reports since its late 2022 launch.
• The Peptide Signal: In the initial quarters following launch, Daxxify experienced a spike in reporting related to "injection site pain" and "headache." This was likely due to the clinical introduction phase, where injectors adjusting to the product's unique reconstitution and diffusion properties reported localized reactions. Over time, the reporting rate has stabilized, aligning with the class baseline.

Academic and Regulatory Safety Context

To evaluate FAERS safety data, we must compare our findings against peer-reviewed benchmarks and official regulatory notices:

1. The Historical Academic Baselines

• Rutgers 2020 Study: Analyzed Botox reports in FAERS and recorded 38,367 adverse events. While providing a useful baseline, it merged therapeutic and cosmetic uses, which inflated the overall risk profile.
• ScienceDirect 2014-2019 Cosmetic Study: This study filtered FAERS to isolate cosmetic-only cases (10,577 reports). It found that 95% of patients were female, with a mean age of 48.4 years. The serious outcome rate was 13.5%, and the top clinical complaints were injection-site pain (9.3%), swelling (6.4%), and eyelid ptosis (6.1%). Our refreshed 2026 slice reports a 16.8% serious rate at the aggregate level, but because that figure pools therapeutic and cosmetic onabotulinumtoxinA, it is not directly comparable to the cosmetic-only 13.5% benchmark; the true cosmetic-only serious rate is likely lower than the aggregate.
• Zargaran 2026 Global Study (PMC): Analyzed global pharmacovigilance databases and recorded 43,809 aesthetic BoNT-A reports, confirming that FAERS accounts for 87.5% (38,321 reports) of all globally recorded adverse events. This makes FAERS the primary dataset for safety analysis.

2. The CDC 2024 Health Advisory

In April 2024, the Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory regarding adverse effects linked to counterfeit or improperly administered botulinum toxin.

• The Event: As of April 18, 2024, the CDC had identified 22 cases of botulism-like illness across 11 states (HAN advisory CDCHAN-00507, issued April 23, 2024). All patients received injections from unlicensed or untrained individuals in non-healthcare settings (such as homes or spas), most for cosmetic purposes. Eleven patients were hospitalized and none died; several received botulinum antitoxin out of concern for distant toxin spread. Notably, among the patients tested, laboratory confirmation of botulism was negative — the illness was "botulism-like" rather than confirmed botulism.
• Clinical Lesson: This advisory highlights that the primary safety risk in aesthetics is not the active pharmaceutical ingredient itself, but rather the qualifications of the injector and the authenticity of the supply chain. Counterfeit toxins often contain uncalibrated doses, leading to severe systemic poisoning.

3. The Public Citizen Petition (2023)

The consumer advocacy group Public Citizen has repeatedly pressed the FDA on botulinum-toxin labeling. Its 2008 petition helped prompt the boxed warning that took effect in 2009, and on December 12, 2023, Public Citizen filed a new citizen petition covering all seven approved botulinum toxin biologics (Botox, Botox Cosmetic, Dysport, Xeomin, Jeuveau, Daxxify, and Myobloc). The 2023 petition asked the FDA to strengthen the boxed warning — arguing that systemic iatrogenic botulism can occur even at recommended doses — and to remove promotional statements it characterized as misleading. The petition illustrates the continuing scrutiny applied to the safety of these products.

Critical Limitations of FAERS Data: What Clinicians Must Know

While FAERS is a powerful tool for signal detection, it has major methodological limitations. Failing to account for these limitations can lead to incorrect conclusions regarding product safety:

[!CAUTION] No Denominator / No Incidence Rate: FAERS records only the numerator (the number of reported adverse events). It does not record the denominator (the total number of doses administered). OnabotulinumtoxinA (Botox/Botox Cosmetic) naturally has the highest number of reports in the database simply because it has been on the market since 1989 and holds the majority of the market share. A higher report count in FAERS does not mean a product is less safe; it typically reflects higher market exposure.

1. Reporting Bias and Under-Reporting

FAERS relies on voluntary reporting from healthcare professionals and consumers, as well as mandatory reporting from manufacturers. Consequently, mild and expected side effects (such as transient bruising, mild headache, or minor asymmetry) are heavily under-reported. Serious, unexpected, or highly publicized events are much more likely to be reported, creating a reporting bias.

2. Lack of Causal Verification

The submission of a report to FAERS does not prove that the drug caused the adverse event. Reports are often incomplete, lack clinical details, and may be influenced by concurrent medications, pre-existing patient comorbidities, or poor injection technique. The FDA does not verify the clinical accuracy of individual reports before adding them to the database.

3. Indication and Coding Noise

Because "Botox" is used for both cosmetic and therapeutic indications, separating the two in the database is challenging. Clinicians often write "Botox" when they administered "Botox Cosmetic," which assigns therapeutic-use complications (such as severe muscle weakness or respiratory events) to the general Botox row. When analyzing toxin safety, researchers must look at cosmetic-specific brands (like Botox Cosmetic, Jeuveau, or Daxxify) to establish an accurate baseline for aesthetic practices.

Frequently Asked Questions (FAQs)

Has anyone died or developed botulism from cosmetic botulinum toxin per FAERS?

While the FAERS database contains records of death and systemic botulism associated with botulinum toxin, these events are extremely rare in cosmetic applications. The vast majority of serious systemic events (such as respiratory failure or death) are associated with high-dose therapeutic injections (e.g., treating severe limb spasticity in pediatric cerebral palsy patients) or the use of unapproved, counterfeit, or highly concentrated non-medical toxins by unlicensed injectors. When administered at standard cosmetic doses (typically under 50-100 units) by a licensed professional using authentic product, the risk of systemic botulism is minimal.

Why does 'drug ineffective' dominate the reaction list, and does that mean the toxin failed?

"Drug ineffective" is the most common reaction term in the database because it serves as the default code for any patient or injector complaint regarding the longevity or strength of the treatment. In many cases, this does not represent a failure of the neurotoxin molecule. Instead, it is driven by expectations (e.g., a patient expecting zero movement for a full 6 months), inappropriate dosing (under-dosing to save costs), incorrect injection placement, or improper product reconstitution and storage.

Is Daxxify safer than Botox based on FAERS report counts?

No. Daxxify’s lower total report count (3,503 reports vs. over 68,000 for Botox and Botox Cosmetic combined) is a reflection of its shorter time on the market (approved in 2022 vs. Botox in 1989) and lower overall utilization volume. FAERS counts cannot be turned into a brand-level safety ranking: report volume tracks exposure, and the brand field lists every co-reported drug in a case, so a per-brand serious rate is not meaningful from this data. No toxin should be judged "safer" from a lower FAERS count.

Strategic Implications for Aesthetic Practices

For medical directors and clinicians managing aesthetic practices, the data from the FAERS database offers clear operational guidance:

• Establish Robust Reconstitution Protocols: With "product preparation error" ranking as a top reporting category, practices must standardize their reconstitution techniques. Toxin activity can degrade rapidly if vials are shaken violently, exposed to high temperatures, or diluted with non-preserved saline. Standardizing these steps minimizes the risk of inefficacy complaints.
• Focus on Technique to Prevent Ptosis: Eyelid ptosis (4.1% of reports) is almost entirely preventable through precise anatomical mapping and dosing. Clinicians should avoid injecting within 1 cm of the supraorbital rim when treating the frontalis muscle and counsel patients to avoid lying down or massaging the face for 4 hours post-treatment.
• Secure the Supply Chain: The CDC's 2024 advisory regarding counterfeit toxins highlights the danger of purchasing products from unauthorized distributors. Medical directors must verify that all injectable products are sourced directly from the FDA-authorized manufacturer or their certified distributors, protecting patients from uncalibrated or contaminated formulations.

Sources

1. US Food and Drug Administration (FDA): openFDA FAERS Drug Adverse Event Dataset
2. US Food and Drug Administration (FDA): FDA Drug Safety Communication — Botox and Botox Cosmetic (Distant Spread of Toxin Effect)
3. Centers for Disease Control and Prevention (CDC): CDC Health Advisory (CDCHAN-00507, April 23, 2024) — Adverse Effects Linked to Counterfeit or Mishandled Botulinum Toxin Injections
4. Annals of Plastic Surgery: Adverse Events Associated With Botox as Reported in an FDA Database (Rutgers, 2020)
5. Journal of Oral and Maxillofacial Surgery: Most Commonly Reported Complications With Cosmetic Botulinum Toxin Type A (FAERS 2014-2019)
6. PMC / Peer-Reviewed: Global Pharmacovigilance of Aesthetic Botulinum Toxin Type A (Zargaran, 2026)
7. US Food and Drug Administration (FDA): FDA Approval History for Daxxify (daxibotulinumtoxinA-lanm)